Deals Corner: Complementary Research on Xencor, Alcatel-Lucent, Xerox, Affiliated Managers and Cheniere
PR Newswire - Fri Dec 19, 8:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Xencor (NASDAQ: XNCR), Alcatel-Lucent (NYSE: ALU), Xerox (NYSE: XRX), Affiliated Managers (NYSE: AMG), and Cheniere (NYSEMKT: LNG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AMG: 213.80 (-0.27), ALU: 3.67 (+0.03), LNG: 71.64 (-0.12), XRX: 14.08 (+0.01), XNCR: 16.83 (+0.77)
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CERS: 6.49 (+0.29), PTRY: 36.78 (+0.28), DRIV: 24.49 (+0.09), MTLS: 9.12 (-0.08), VOLC: 17.95 (+0.02), NPSP: 35.06 (+1.18), NYNY: 7.89 (+0.32), XNCR: 16.83 (+0.77), AREX: 6.98 (-0.11)
Xencor, Inc. (XNCR) in Focus: Stock Soars 29.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:21AM CST
Xencor, Inc. (XNCR) was a big mover last session, as the company saw its shares rise by nearly 30% on the day.
ACRX: 6.61 (+0.06), XNCR: 16.83 (+0.77)
Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies
PR Newswire - Thu Dec 18, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has entered into a collaboration and licensing agreement with Novo Nordisk to jointly discover novel biologic drug candidates for an undisclosed target by combining multiple Xencor XmAb® technologies, including bispecific and immune inhibitor technologies. Xencor is eligible to receive up to approximately $175 million in upfront payments, research support, and pre-clinical and clinical development, regulatory and sales milestones, in addition to future royalties.
NVO: 43.80 (+1.08), XNCR: 16.83 (+0.77)
Market Maker Surveillance Report. SFY, NES, GASL, MDBX, TTPH, XNCR, Winning Stocks With Lowest Price Friction For Wednesday, December 17th 2014
M2 - Thu Dec 18, 12:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4931 companies with "abnormal" market making, 4995 companies with positive Friction Factors and 2119 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Swift Energy Co (NYSE:SFY), M/S GBCPN 3 GBL INDS (NYSE:NES), Direxion Daily Natural Gas Related Bull 2x Shares (NYSE:GASL), (OTC:MDBX), (NASDAQ:TTPH), (NASDAQ:XNCR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
TTPH: 38.86 (+0.53), GASL: 4.67 (-0.22), NES: 4.96 (-0.44), SFY: 4.47 (-0.06), XNCR: 16.83 (+0.77)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 11:46AM CST
PTRY: 36.78 (+0.28), VIP: 4.07 (-0.26), CCM: 5.87 (-0.11), HGSH: 4.60 (-0.06), CLF: 6.06 (-0.09), ASPX: 49.93 (-0.10), SN: 9.91 (-0.71), NVGN: 2.40 (-0.09), NYNY: 7.89 (+0.32), FVE: 4.03 (-0.03), DRIV: 24.49 (+0.09), SGNL: 2.22 (-0.01), RT: 6.30 (+0.10), SFY: 4.47 (-0.06), VOLC: 17.95 (+0.02), WRES: 1.66 (-0.13), SGNT: 25.58 (+0.31), BBLU: 1.15 (-0.03), POZN: 7.86 (+0.07), XNCR: 16.83 (+0.77)
MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 6:56AM CST
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Xencor Inc. (NASDAQ: XNCR) today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. MOR208 was in-licensed by MorphoSys from Xencor in 2010.
XNCR: 16.83 (+0.77)
Xencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference
PR Newswire - Thu Dec 04, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 25th Annual Oppenheimer & Co. Healthcare Conference on Thursday, December 11, 2014 at 11:30 a.m. EST in New York, New York.
XNCR: 16.83 (+0.77)
Xencor to Present at the 2014 Deutsche Bank BioFEST Conference
PR Newswire - Tue Nov 25, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 2014 Deutsche Bank BioFEST Conference on Tuesday, December 2, 2014 at 4:35 p.m. EST in Boston, Massachusetts.
DB: 30.95 (+0.04), XNCR: 16.83 (+0.77)
Xencor's (XNCR) CEO Bassil Dahiyat on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:29PM CST
XNCR: 16.83 (+0.77)
Xencor misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:35PM CST
XNCR: 16.83 (+0.77)
Xencor Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:01PM CST
Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the third quarter ended September 30, 2014 and provided a review of recent business highlights.
XNCR: 16.83 (+0.77)
Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting
PR Newswire - Thu Nov 06, 8:09AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that preclinical data from three programs using the company's XmAb(r) bispecific Fc technology show that targeting CD123, CD20 and CD38 antigens each activated T-cells to rapidly kill target cells from a single dose IV bolus in cynomolgus monkeys and demonstrated prolonged half-life of approximately one week in mice. This data, and additional data on primate pharmacokinetics, efficacy and tolerability, will be presented in three poster presentations at the upcoming American Society of Hematology (ASH) 2014 Annual Meeting in December 2014. The abstracts were made public today on the ASH 2014 website at http://www.hematology.org/Annual-Meeting.
XNCR: 16.83 (+0.77)
Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference
PR Newswire - Tue Nov 04, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 at 2:30 p.m. MT in Phoenix, Arizona.
XNCR: 16.83 (+0.77)
Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call
PR Newswire - Mon Nov 03, 7:00AM CST
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release third quarter financial results after the market closes on Monday, November 10, 2014. Xencor's management team will host a webcast and conference call the same day at 4:30 p.m. EST (1:30 p.m. PST) to discuss the financial results and provide a corporate update.
XNCR: 16.83 (+0.77)
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease
PR Newswire - Tue Oct 28, 3:00PM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has regained all development and commercial rights to XmAb®5871 by seeking and obtaining a termination of the prior option and collaboration agreement and executing a new right-of-first-negotiation agreement with Amgen. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary immune inhibitor XmAb Fc domain that targets FcRIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a clinical trial in patients with moderate-to-severe rheumatoid arthritis (RA) and topline results are expected by the end of 2014. The company is planning clinical development in multiple autoimmune diseases where B-cell inhibition shows promise, including IgG4-related disease.
AMGN: 160.67 (+3.15), XNCR: 16.83 (+0.77)
Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel
PR Newswire - Tue Sep 02, 7:00AM CDT
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack, M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland, senior vice president, chief compliance officer and general counsel.
XNCR: 16.83 (+0.77)